Insilico Medicine
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1000 Massachusetts Ave Ste 126, Cambridg...Website
www.insilico.comRevenue
$63.4 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
3
3
1
1
2
About Insilico Medicine
Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms that utilize deep generative models, reinforcement learning, transformer, and other modern machine learning techniques for novel target discovery and generation of novel molecular structures with desired properties. It is developing breakthrough solutions for the discovery and development of innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and aging-related diseases.Explore more
Insilico Medicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Insilico Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Insilico Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Insilico Medicine launches new products
Check out if Insilico Medicine is spiking on competitors!
Check if Insilico Medicine has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Insilico Medicine has new funding data
Click to see if Insilico Medicine had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Insilico Medicine
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Insilico Medicine recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Insilico Medicine is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Insilico Medicine is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Insilico Medicine.
Insilico Medicine financials insights
Gather financial insights about Insilico Medicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$2.8M
2017
Private Equity
$4M
2018
Series A
$6M
2019
Series B
$37M
2021
Series C
$255M
2022
Series D
$95M
2025
Series E
$110M
Insilico Medicine Tech Stack
A closer look at the technologies used by Insilico Medicine
Most Recent Scoops
Person-Based
Machine Learning, Pharmaceuticals
Person-Based
Pain Point, Artificial Intelligence, Patient Experience
Person-Based
Clinical Operations
Person-Based
Business Development, Clinical Operations
Event
Product Marketing, Events, Sales, Digital Technology, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology, Operations, Patient Experience, Telemedicine
Insilico Medicine News & Media
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the clinical potential in advanced mesothelioma. ISM6331 is a novel, potential best-in-class, pan-TEAD inhibitor engineered via Chemistry42 to...Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors...Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain-penetrant, non-opioid solution for pain management. Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated superior efficacy compared to the standard of care, along with a favorable safety profile as an oral treatment, and promising DMPK properties. Proven Reproducibility and Scale: As Insilico's 31st PCC nominated sinceInsilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 15, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX: BORAY), a glob
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Insilico Medicine
Sign Up For FreeTo access detailed company insights
Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms that utilize deep generative models, reinforcement learning, transformer, and other modern machine learning techniques for novel target discovery and generation of novel molecular structures with desired properties... Read More
